What did @drjuliodiazpinillos actually say?
Honestly, the transcript here is nearly unusable. The auto-generated captions for this video produced garbled, incoherent text that does not reflect the spoken content, making it impossible to quote the creator directly with confidence. What we can work with is the caption the creator wrote themselves, which is considerably more informative.
In the caption, Dr. Diaz Pinillos claims that testosterone pellets, marketed under the hashtag "chipdetestosterona" and tagged as "rejuvchip," produce favorable effects on sleep quality, mood, energy, muscle development, libido, and general quality of life. He also states that hormonal production declines with age, framing pellet therapy as a corrective intervention. This is a patient testimonial video, not a clinical presentation, so the claims are filtered through one person's reported experience rather than any measurable outcome data.
Does the science back this up?
Partially, but with important caveats that the video skips entirely. Testosterone replacement therapy in men with clinically confirmed hypogonadism does have documented benefits in several of these areas, but the evidence is nowhere near as clean as a testimonial video implies.
The 2023 TRAVERSE trial (Lincoff et al., New England Journal of Medicine) remains the most rigorous recent data point. It found TRT in middle-aged men with hypogonadism did not increase major cardiovascular events compared to placebo, which was somewhat reassuring, but it also showed that sexual function improvements were modest and inconsistent. On libido and energy, benefits are real but effect sizes vary considerably depending on baseline testosterone levels.
For sleep, the picture is messier. A 2015 meta-analysis by Bhasin et al. in the Journal of Clinical Endocrinology and Metabolism found that testosterone therapy can worsen sleep-disordered breathing in some men, particularly those with existing subclinical sleep apnea. Claiming sleep improvement as a broad benefit is, at best, an oversimplification.
Muscle development benefits are real in men with confirmed low testosterone, but studies like Snyder et al. (2016, NEJM) showed modest gains in lean mass, not dramatic body composition changes. Framing this as a performance benefit without acknowledging the clinical threshold matters.
What did they get wrong (or right)?
Credit where it is due: testosterone does decline with age. This is well-established physiology. The average decline is roughly 1-2% per year after age 30 (Harman et al., 2001, Journal of Clinical Endocrinology and Metabolism). For men who have clinically confirmed hypogonadism, defined as consistently low serum testosterone with symptoms, treatment is a legitimate medical intervention with a reasonable evidence base.
What the video gets wrong is the framing. Pellets specifically introduce a delivery problem that injectable or gel formulations do not have to the same degree. Once a pellet is implanted, you cannot adjust the dose if levels run high or if side effects emerge. Studies on pellet pharmacokinetics, including work by Bhattacharya et al. (2021, Sexual Medicine Reviews), note that supraphysiologic testosterone levels in the first weeks post-implantation are common and can elevate hematocrit and estradiol in ways that are difficult to manage quickly.
A patient testimonial is also not evidence. One person feeling better after a procedure tells you almost nothing about whether the procedure caused that improvement, what the baseline was, or what risks they may not yet have experienced.
What should you actually know?
If you are considering testosterone therapy, the delivery method matters more than most social media content suggests. Pellets are not superior to injectables or transdermal gels in terms of clinical outcomes, and their irreversibility is a real limitation, not a minor footnote.
Before anyone prescribes testosterone in any form, you need a confirmed diagnosis. That means at least two morning serum testosterone measurements below the clinical threshold, plus documented symptoms. Treating age-related decline in a man with normal testosterone levels is a different conversation than treating hypogonadism, and conflating the two is how people end up on unnecessary hormones.
The hashtag "antiaging" in this video is a red flag. Testosterone is not an anti-aging drug. It is a hormone replacement therapy for a specific deficiency state. The FDA has not approved it for age-related decline in the absence of diagnosed hypogonadism, and prescribing it for wellness optimization sits in a regulatory and ethical gray zone that patients deserve to understand before they commit to a subcutaneous implant they cannot remove.
If you are working with a telehealth provider on TRT, ask specifically what your baseline labs showed, what delivery method is being recommended and why, and how dose adjustments are handled if your levels come back too high.